Healthcare Disruptors: AI, Telehealth and Cost Savings

By Mark Sheridan

Mar 27, 2025

3 min read

UnitedHealth, Elevance Health, Cigna, and Medicus Pharma are driving AI, telehealth, and value-based care to transform patient outcomes and cost efficiency.

Healthcare Disruption Using AI to Advance Medical and Pharmaceutical Patient Care

Recent innovations in healthcare are reshaping patient care through breakthrough therapies, data-driven efficiencies, and value-based care models. Leading companies are leveraging artificial intelligence, digital health solutions, and novel treatment approaches to enhance access, affordability, and outcomes. Key players driving these advancements include Medicus Pharma Ltd (NASDAQ: MDCX), UnitedHealth Group Inc (NYSE: UNH), Elevance Health Inc (NYSE: ELV), and Cigna Group (NYSE: CI).

UnitedHealth is expanding value-based care, aligning provider incentives with patient outcomes to enhance preventive care and cost efficiency. Elevance Health is leveraging artificial intelligence, predictive analytics, and strategic acquisitions to improve care coordination. Meanwhile, Cigna integrates telehealth, remote monitoring, and AI-driven insights to enhance care delivery, chronic disease management, and mental health support. Together, these companies are driving a shift toward patient-centric, technology-enabled healthcare solutions that improve outcomes while reducing costs.

Medicus Pharma Ltd (NASDAQ: MDCX) is advancing a Phase 2 clinical trial for a microneedle patch treatment targeting basal cell carcinoma (BCC)1 - the most common cancer worldwide2. With strong patent protection, the SkinJect patch is a non-invasive, painless, and cost-effective alternative to surgery. A small, thumb-sized microneedle patch is applied to the skin over the BCC lesion. The patch is painless and easy to administer in a doctor’s office and can be applied during just three weekly 30-minute visits over 2 weeks. This has the potential to provide a simple and affordable solution to BCC patients seeking better treatment options. With over 5 million BCC cases diagnosed annually in the U.S., Medicus Pharma targets a $2 billion share3 of the $15 billion North American skin cancer market. Its SkinJect patch has projected development costs of $75–$100 million, far below the $648 million industry average4. Priced at around $1,000, it offers a cost-effective alternative to Mohs surgery ($1,800–$2,500)5.

UnitedHealth Group Inc (NYSE: UNH) continues to lead in value-based care models, which prioritize patient outcomes over traditional fee-for-service models. This strategy has driven significant growth, with 2.1 million new domestic consumers and 600,000 additional value-based care patients in 20246. This approach aims to align provider incentives with patient health outcomes, promoting preventive care and better management of chronic conditions. Unlike fee-for-service models, which reimburse providers based on the volume of services, value-based care emphasizes quality and cost efficiency. UnitedHealth also invests in AI to streamline administrative processes and improve customer service, reinforcing its commitment to cost-effective healthcare solutions.

Elevance Health Inc (NYSE: ELV) is a leading health insurance provider leveraging advanced technology, strategic acquisitions7, and data-driven healthcare solutions to enhance care delivery and efficiency. The company has expanded its data capabilities through the acquisition of Granular8, a subsidiary of Alphabet’s Verily, specializing in risk analysis and employer-driven healthcare cost management. Additionally, Elevance integrates personalized care models that prioritize preventive health, virtual care, and social determinants of health to improve patient outcomes. By focusing on digital transformation and strategic growth, Elevance continues to enhance healthcare access, affordability, and efficiency for individuals, employers, and providers9.

Cigna Group (NYSE: CI) integrates digital health solutions to enhance care delivery, chronic disease management, and mental health support. Through its Evernorth subsidiary, Cigna employs machine learning for risk prediction and personalized health plan development, improving efficiency and patient outcomes. The company leverages telehealth10, AI-driven analytics11, and remote patient monitoring to enhance access to healthcare services and optimize efficiency. These innovations support early intervention, tailored treatment plans, and improved chronic disease management, ultimately contributing to cost savings across its network. Beyond technological advancements, Cigna is addressing the growing youth mental health crisis through targeted grant funding12 and partnerships with community-based programs. These initiatives focus on early intervention, increasing mental health literacy, and expanding access to essential resources for young individuals, caregivers, and schools. By supporting scalable solutions, Cigna aims to reduce barriers to care and improve adolescent well-being.

Leading healthcare companies are transforming patient care through various initiatives. UnitedHealth is expanding preventive care and cost-efficient value-based models, while Elevance Health leverages AI and strategic acquisitions to enhance care coordination. Cigna integrates telehealth and remote monitoring to improve access and chronic disease management. Meanwhile, Medicus Pharma’s SkinJect patch is undergoing clinical trials as a potential non-invasive, cost-effective alternative for basal cell carcinoma treatment, highlighting the industry's shift toward patient-centric innovation. Discover more about Medicus in our exclusive investor report.

Related Articles:

Explore more on these topics:

Pharmaceuticals Biotechnology Healthcare

Important Notice And Disclaimer

PAID ADVERTISEMENT

This communication is a paid advertisement. ValueTheMarkets is a trading name of Digitonic Ltd, and its owners, directors, officers, employees, affiliates, agents and assigns (collectively the “Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by Medicus Pharma to conduct investor awareness advertising and marketing and has paid the Publisher the equivalent of one hundred and seventy five thousand US dollars starting 3rd March 2025 for a period of 4 weeks until 28th March 2025 to produce and disseminate this and other similar articles and certain related banner advertisements. This compensation should be viewed as a major conflict with the Publisher’s ability to provide unbiased information or opinion.

CHANGES IN SHARE TRADING AND PRICE

Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to adversely affect share prices. Frequently companies profiled in our articles experience a large increase in share trading volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in share trading volume and share price may likely occur.

NO OFFER TO SELL OR BUY SECURITIES

This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security.

INFORMATION

Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position.

This communication is based on information generally available to the public and on an interview conducted with the company’s CEO, and does not contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher does not guarantee the accuracy or completeness of the information. Further, the information in this communication is not updated after publication and may become inaccurate or outdated. No reliance should be placed on the price or statistics information and no responsibility or liability is accepted for any error or inaccuracy. Any statements made should not be taken as an endorsement of analyst views.

NO FINANCIAL ADVICE

The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser or a financial adviser. The Publisher has no access to non-public information about publicly traded companies. The information provided is general and impersonal, and is not tailored to any particular individual’s financial situation or investment objective(s) and this communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor or a personal recommendation to deal or invest in any particular company or product. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR+ and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results.

FORWARD LOOKING STATEMENTS

This communication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. Statements in this communication that look forward in time, which include everything other than historical information, are based on assumptions and estimates by our content providers and involve risks and uncertainties that may affect the profiled company’s actual results of operations. These statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results and performance to differ materially from any future results or performance expressed or implied in the forward-looking statements. These risks, uncertainties and other factors include, among others: the success of the profiled company’s operations; the size and growth of the market for the company’s products and services; the company’s ability to fund its capital requirements in the near term and long term; pricing pressures; changes in business strategy, practices or customer relationships; general worldwide economic and business conditions; currency exchange and interest rate fluctuations; government, statutory, regulatory or administrative initiatives affecting the company’s business.

INDEMNIFICATION/RELEASE OF LIABILITY

By reading this communication, you acknowledge that you have read and understand this disclaimer in full, and agree and accept that the Publisher provides no warranty in respect of the communication or the profiled company and accepts no liability whatsoever. You acknowledge and accept this disclaimer and that, to the greatest extent permitted under applicable law, you release and hold harmless the Publisher from any and all liability, damages, injury and adverse consequences arising from your use of this communication. You further agree that you are solely responsible for any financial outcome related to or arising from your investment decisions.

TERMS OF USE AND DISCLAIMER

By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here https://www.valuethemarkets.com/terms-conditions/ and acknowledge that you have reviewed the Disclaimer found here https://www.valuethemarkets.com/disclaimer/. If you do not agree to the Terms of Use, please contact valuethemarkets.com to discontinue receiving future communications.

INTELLECTUAL PROPERTY

All trademarks used in this communication are the property of their respective trademark holders. Other than valuethemarkets.com, the Publisher is not affiliated, connected, or associated with, and the communication is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks other than valuethemarkets.com.

AUTHORS: VALUETHEMARKETS

valuethemarkets.com and Digitonic Ltd and our affiliates are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above. This article does not provide any financial advice and is not a recommendation to deal in any securities or product. News and research are not recommendations to deal, and investments may fall in value so that you could lose some or all of your investment. Past performance is not an indicator of future performance.

ValueTheMarkets do not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above piece. ValueTheMarkets have been paid to produce this piece by the company or companies mentioned above. Digitonic Ltd, the owner of valuethemarkets.com, has been paid for the production of this piece by the company or companies mentioned above.